BioSpace News Archive

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, is scheduled to participate in a fireside chat at the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, Jan. 5, 2023, at 8:55 a.m. ET.

Orthofix Medical Inc. today announced results from a prospective, multicenter clinical study evaluating the safety and efficacy of the Trinity Elite ™ cellular bone allograft (CBA) in lumbar spinal fusion procedures.

Oragenics, Inc. today announced results indicating no toxicity signals or adverse events from its Good Laboratory Practices (GLP) toxicology study in rabbits evaluating the safety and immunogenicity of its NT-CoV2-1 intranasal vaccine candidate.

Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines.

NanoString Technologies, Inc. today announced that the company’s management is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference.

AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM) Initiation of AFM28 clinical development in the first half of 2023 on track.

Bausch Health Companies Inc. today announced that its new topical prescription treatment for acne vulgaris, ARAZLO TM (tazarotene lotion, 0.045% w/w), is now available to patients.

BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders.

Elite Pharmaceuticals, Inc. today announced that it filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists.

Microbix Biosystems Inc. reports results for its year and fourth quarter ended September 30, 2022, with record sales and continued positive net earnings, plus ongoing progress upon its strategic goal of increasing its capacity for medical devices production and, over time, to thereby grow sales, margins, and earnings.